CannAssist International Corp. (CNSC) Focused on Leveraging Position in Growing Cannabis Industry through Strategic Marketing Plan

  • Vast opportunities exist in growing cannabis space
  • CannAssist is committed to establishing aggressive marketing presence in promising market
  • CannAssist brings impressive advancements, achievements to the table, including its propriety CiBiDinol technology

Carefully developing and executing a strategic go-to-market plan has never been more important for companies operating in the cannabis industry, according to a recent “Rolling Stone” article (https://cnw.fm/uMoi5). The article urges cannabis companies to consider the industry from both a competitive perspective as well as an opportunity angle, which is exactly what CannAssist International (OTCQB: CNSC) has done as it looks toward 2021 and a projected $5.8 million share of the market.

“The 2020 election was another exciting turning point: Four new states joined the 12 existing markets with legal recreational cannabis, bringing adult use to 15 regions in just eight short years,” the “Rolling Stone” article reported. “Nearly one in three Americans now live in a state where those aged 21 and older can purchase and possess cannabis freely. This will likely expand significantly with the addition of more East Coast markets poised to legalize in the near future through legislation in New York, Pennsylvania and Connecticut.

“It gets even better,” the article continued. “With a new federal administration comes the likelihood of a mandate to decriminalize cannabis and a path to legalization through bills in Congress such as the passing of the MORE Act by the House of Representatives, with its lead sponsor Vice President Kamala Harris. Consumer sentiment favoring legalization is expanding. According to findings from Pew Research from 2019, two-thirds of Americans approve of adult-use in what has become one of those rare bipartisan issues with differences of opinion occurring predominantly along generational lines.”

CannAssist recognizes the wave of opportunity flooding the cannabis market and is committed to establishing an aggressive marketing presence using tactics across the entire marketing funnel plan as part of its go-to-market strategy (https://cnw.fm/cDw0H). In part, the company will focus on retail partnership, brand collaborations and influencer programming. In addition, CannAssist is eyeing large-scale video and content capture and will also evaluate avenues for digital advertising, email marketing, and both paid and organic social media engagement.

These efforts are designed to support the company’s efforts to reach its goals in five key product areas: Xceptol Capsules M($1 million), Xceptol Drops ($532,000), Xceptol Pain Cream ($1.27 million), Xceptol Pet product ($130,000), and raw material from its Xceptor Labs ($1.48 million). CannAssist owns Xceptor Labs, which produces and markets the Xceptol brand product line and also produces superior quality raw materials for third-party company use.

A biotechnological pharmaceutical and wellness company, CannAssist brings impressive advancements and achievements to the table—none more notable than its development of CiBiDinol, which simply put is cannabidiol made water compatible (https://cnw.fm/JGyB1). CiBiDinol addresses critical issues regarding CBD molecules, including delivery, bioavailability and short shelf life, by offering predictable potency, reduced dosage requirements and a wider variety of product forms.

Established in May 2017, CannAssist is headquartered in San Diego County, California, and markets its consumer line of cannabidiol (“CBD”) products under the Xceptol brand. CNSC is currently targeting North America, Central America, South America, South Africa, the EU, the UK and the Philippines as viable product markets. The company has established strategic partnerships in sourcing, manufacturing, processing, laboratory, distribution, public relations and legal representation.

For more information, visit the company’s website at www.CannAssistInternational.com.

NOTE TO INVESTORS: The latest news and updates relating to CNSC are available in the company’s newsroom at https://cnw.fm/CNSC

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

420 with CNW — New Congressional Bill Could Allow CBD, Hemp to Be Sold as Dietary Supplements

The 2018 Farm Bill legalized the cultivation and sale of industrial hemp and hemp extracts, including cannabidiol (“CBD”), spawning what would soon be one of the most popular health and wellness ingredients in a long time. With both hemp and CBD boasting a wide array of benefits, a market products containing the two ingredients sprang up. Although the sector soon had thousands of sellers across the supply chain with CBD products attracting incredible demand, the U.S. Food and Drug Administration (“FDA”) was expressly against marketing and selling CBD products as dietary supplements.

However, thanks to a bill reintroduced into Congress by a bipartisan group of lawmakers, that may soon be a thing of the past. The bill, which was first filed by Representatives Kurt Schrader and Morgan Griffith last year, would allow hemp, hemp-derived CBD, and “any other ingredient derived from hemp” to be used as a dietary supplement under the Federal Food, Drug, and Cosmetic Act. This version of the bill, called the Hemp and Hemp-Derived CBD Consumer Protection and Market Stabilization Act, has 17 other cosponsors alongside the two congressmen.

For quite a while, the FDA has been under pressure to rein in the quickly growing CBD industry, called the “Wild West” by some. However, the agency has maintained that it may take a while to fully regulate CBD, offering enforcement discretion guidance in the meantime while it works on crafting formal rules for CBD. In 2019, a bipartisan coalition of 26 House members sent the FDA a letter saying that the agency’s current regulatory posture has led to significant “regulatory and legal uncertainty.”

The FDA opened a public comment period from April to July of 2019 asking the public to submit information about CBD; the agency reopened the comment period in March 2020. According to the agency, the comment period would allow stakeholders to provide new information in real time to the FDA that would help it “address uncertainties and data gaps” as it crafted CBD regulation.

The U.S. Hemp Roundtable has applauded the move, saying Schrader and Griffith have shown true leadership concerning CBD. Jonathan Miller, general counsel for the Roundtable, anticipates support for the CBD legislation will continue to build as it goes through Congress. The new bipartisan CBD marketing bill increases the number of bills addressing cannabis issues. The second is a bill to move cannabis’ place in the Controlled Substances Act from Schedule I to Schedule III; a third bill prevents the U.S. Department of Veterans from keeping veterans from accessing their benefits because of state-legal medical marijuana use.

In states with legal cannabis markets, innovation in the sector is booming. A clear example is the way in which CannAssist International Corp. (OTCQB: CNSC) is merging the worlds of biotechnology, the wellness industry and the pharmaceuticals industry to create cannabis products that offer consistent results and superior performance in many aspects, including better bioavailability.

NOTE TO INVESTORS: The latest news and updates relating to CannAssist International Corp. (OTCQB: CNSC) are available in the company’s newsroom at https://cnw.fm/CNSC

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — CBD May Be the Remedy for Gonorrhea and Other Bacterial Diseases

A report from a team of researchers from the University of Australia, published in “Nature,”  has demonstrated how synthetic cannabidiol (“CBD”) can eliminate various bacteria responsible for ailments such as Legionnaires’ disease, meningitis and gonorrhea. The report suggests that CBD could bring about a class of new antibiotics for resistant bacteria in a few decades to come.

The researchers tested CBD’s antimicrobial activity using lab models to imitate a two-week patient treatment. This would enable the researchers to observe how rapidly the bacteria mutated to try to outmaneuver cannabidiol’s power to eliminate them. The study’s abstract reported that the researchers discovered that CBD could selectively eliminate a subset of Gram-negative bacteria that included the Neisseria gonorrhea pathogen.

Mark Blaskovich, an associate professor at the university, stated that through a partnership with Botanix Pharmaceuticals, which provided expertise on different formulations, the researchers showed how CBD could penetrate and eliminate various bacteria.

Blaskovich explained that this was the first time a study evaluating how cannabidiol could eliminate certain types of Gram-negative bacteria had been conducted. He continued, stating that the bacteria possessed an additional outer membrane, like an extra line of defense, which made it all the more difficult for antibiotics to infiltrate them.

Blaskovich then mentioned that the researchers hypothesized that CBD eliminated the bacteria by piercing through the outer cell membranes. However, the researchers weren’t sure exactly how CBD did so, citing that they need to conduct further research. He added that cannabidiol had demonstrated a low propensity to create resistance in bacteria.

In addition to this, the researchers also found that the effectiveness of the molecular structure of cannabidiol only changed slightly. Blaskovich noted that this was exciting because it has been decades — since the 1960s — since antibiotics of new molecular classes for Gram-negative infections had been found and approved. Now, he said, researchers could consider developing new cannabidiol analogs in improved properties.

Botanix executive chairman and president Vince Ippolito mentioned in the same statement that the published research demonstrated that synthetic cannabinoids had huge potential as antimicrobials. He then announced that the company was ready to commercialize usable antimicrobial treatments, which he hoped would be accessible to more patients in the future; he noted that the partnership with the university had enabled the company to begin clinical trials on a topical cannabidiol formulation.

Ippolito also added that the clinical results of phase 2a were expected soon, and he hoped that this would open the way for treatments for legionnaires’ disease, meningitis and gonorrhea.

Meanwhile, CBD products have been facing a number of challenges, such as limited shelf life, low bioavailability and poor water solubility. CannAssist International Corp. (OTCQB: CNSC) says it has made improvements regarding those challenges through its line of Xceptol brand products.

NOTE TO INVESTORS: The latest news and updates relating to CannAssist International Corp. (OTCQB: CNSC) are available in the company’s newsroom at https://cnw.fm/CNSC

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Could Canna-Tourism Trigger Economic Recovery?

Just as the global economy was finally recovering from the 2007–2008 financial crisis, the coronavirus pandemic struck, effectively plunging the world into the worst recession since World War 2. International travel came to a near-total standstill as countries tried to prevent the virus from entering their borders, disrupting global supply chains. The resultant lockdown and self-distancing orders were devastating for most industries; one of the hardest hit was the hospitality sector, which shouldered millions of lost jobs.

The cannabis industry fared relatively well, on the other hand, with cannabis companies reporting month-over-month sales records even as the pandemic ravaged the economy. In the United States, states with legal cannabis markets such as California collected as much as $2 billion in cannabis tax revenue. A year after the virus first appeared in Wuhan, China, countries are looking to rebound from the 2020 economic slump, and cannabis tourism represents quite a lucrative opportunity.

With several states and countries adopting pro-cannabis policies, people residing in jurisdictions that don’t allow cannabis have been traveling to those that do to purchase and consume cannabis. Dubbed cannabis tourism, the “New York Times” reported that the phenomenon was on the rise in 2019, with travel entrepreneurs organizing cannabis-infused experiences such as bus tours of grow facilities, food classes and painting classes.

Research from the Colorado Tourism Office (“CTO”) and partner Strategic Marketing and Research Insights (“SMARI”) reveals that for 6.5% of the people who traveled to Colorado between 2013 and 2018, cannabis was one of the reasons they visited the state. Additionally, 16% of travelers who visited the state in winter 2018–2019 and 15% of 2018 summer travelers also visited a cannabis dispensary or store. SMARI found that cannabis-motivated visitors tend to have longer trips compared to the average visitor, spending 5.1 nights in the state versus 4.6 nights.

And this type of tourism is not confined to just the U.S.; Thailand is planning Southeast Asia’s first-ever medical cannabis tours in 2021 to attract foreign investment, and Canada is evaluating how to use its flourishing cannabis industry to help revive the economy as well as boost national and international tourism. Countries such as Spain, Germany, Jamaica and Uruguay also offer a variety of cannabis-infused experiences to cannabis tourists.

With businesses offering a wide range of exciting cannabis-inspired experiences coupled with higher-value cannabis products such as vape pens and topical creams, cannabis tourism can provide plenty of revenue for countries, states and cities looking to rebound from the COVID-19 recession.

Away from Canna-tourism, many cannabis companies have taken innovation to a whole new level. A clear illustration is the work being done by CannAssist International Corp. (OTCQB: CNSC) through its fully owned Xceptor Labs, which has introduced CBD tinctures, creams, pet drops and capsules with higher absorption levels into the market.

NOTE TO INVESTORS: The latest news and updates relating to CannAssist International Corp. (OTCQB: CNSC) are available in the company’s newsroom at https://cnw.fm/CNSC

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Massachusetts Cannabis Firms’ Association Drops Lawsuit Challenging Cannabis Delivery Regulations

A business group that represents many of the cannabis shops in the state of Massachusetts had announced that it will be dropping the legal challenge it filed to block new marijuana industry regulations that allowed home delivery.

The Commonwealth Dispensary Association (“CDA”) declared in its suit that the Cannabis Control Commission’s (“CCC”) new delivery-only licenses infringed on the cannabis laws of the state, which already gave retailers the right to deliver marijuana under their current licenses.

In a statement the CDA had filed earlier this month, the association stated that the CCC had gone against its authority and ignored the laws of the state by completely overturning already-established rules that many small businesses had been observing in their operations since 2016.

The “Boston Globe” reported that in the days following the suit, New England Treatment Access, which is among the biggest cannabis firms in the state with shops in Brookline and Northampton, left the CDA. Cultivate, another firm that has shops in Framingham and Leicester, and an estimated 10 additoinal firms also left the dispensary association.

The new regulations introduced by the CCC created two types of delivery licenses:

  • A cannabis courier license, which allows one to charge fees to make deliveries from dispensaries and retailers that are licensed by the CCC
  • A cannabis delivery operator license, which allows one to purchase products wholesale from manufacturers and growers and sell them to their own consumers

Advocates insist that these licenses will level the playing field between small businesses and big corporations, as the barriers for obtaining a delivery license are not as demanding as those that govern obtaining a retail license.

After dropping its suit, the CDA promised to work with groups such as Massachusetts Cannabis Association for Delivery (“MCAD”) to achieve mutual goals, such as increasing the participation of different entrepreneurs in the cannabis industry.

MCAD president Christopher Fevry stated that his association was pleased to know that the CDA had dropped the filed charges but added that it would still not be enough; he noted that well-capitalized and established firms need to be willing to take concrete steps towards ensuring the marijuana industry in Massachusetts is not only fair but also equitable.

On the other hand, the Cannabis Business Association (“CBA”), which had backed the delivery regulations introduced by the CCC, stated that it was glad to see the CDA drop its suit, mentioning that it would continue working with regulators and advocates to address various disparities in the state’s marijuana industry.

Meanwhile, California-based CannAssist International Corp. (OTCQB: CNSC) offers a proprietary technology (CiBiDinol) and exclusive products made using that technology that have undergone independent lab testing which has confirmed that they are 400% better able to penetrate the skin in comparison to conventionally made topical products.

NOTE TO INVESTORS: The latest news and updates relating to CannAssist International Corp. (OTCQB: CNSC) are available in the company’s newsroom at https://cnw.fm/CNSC

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Arizona Residents May Soon Be Able to Purchase Recreational Marijuana

Residents of Arizona who are 21 years or older may soon be able to purchase cannabis, after state health officials revealed that they would begin issuing licenses for recreational marijuana sales.

Existing medical cannabis dispensaries will be the first stores able to sell cannabis and recreational cannabis products such as gummy edibles. Some of these businesses stated last week that they were awaiting online approval from state regulators so they could begin selling their products to individuals who possessed an ID issued by the state. A Department of Health Services spokesman stated that as of Tuesday, Jan. 19, 40 medical dispensaries had submitted their applications to sell recreational cannabis.

The unexpected change of heart with regard to licenses by the state has afforded the businesses that did apply for licenses a competitive advantage, considering that nearly two-thirds of dispensaries in Arizona are yet to make or submit their applications. Raúl Molina, senior vice president of operations at the Mint Dispensaries, which is among the operations that have already submitted applications, stated that the company was prepared to start sales as soon as it received approval.

Molina explained that the company had stocked up on childproof packaging, purchased an extra 800 pounds of cannabis in anticipation of a growth in demand, and submitted the documents required by the state for his employees to work in a recreational cannabis dispensary. Molina added that he had allotted registers for medical cannabis patients, which would prevent them from being displaced by new recreational cannabis consumers.

Voters of Arizona approved Proposition 207 last year during the November elections. The measure’s approval legalized the possession and use of cannabis in the state. The proposal also permitted the state’s operating medical cannabis dispensaries to apply for licenses to sell their products to individuals aged 21 and above, instead of only those who possessed a medical cannabis card issued by the state.

The state is required to issue recreational licenses to any medical dispensary that has complied with regulations within 60 days of receiving the application. In fact, business owners will not even have to wait that long. This is because the Department of Health Services sent an email to dispensaries on Friday stating that it was excited to establish the adult-use cannabis program and noting that adult sales would start this month.

Consumers should note that they will be expected to pay in cash, as a majority of dispensaries will be operating on cash-only basis because of bank restrictions. Additionally, while medical cannabis patients can receive their purchases delivered to them from various dispensaries, recreational purchases currently have to be made in person.

Away from the expected recreational cannabis sales in Arizona, California-based CannAssist International Corp. (OTCQB: CNSC) has brought to market proprietary technology that enables it to lower the needed dosage of CBD products since the molecules of cannabidiol are altered to increase their bioavailability.

NOTE TO INVESTORS: The latest news and updates relating to CannAssist International Corp. (OTCQB: CNSC) are available in the company’s newsroom at https://cnw.fm/CNSC

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Wyoming Taking Cannabis Legalization Notes from Neighbors

Wyoming is among the last few states in the United States that has not yet accepted legal marijuana in some form. The state is surrounded by states such as Montana and South Dakota that have legalized cannabis, and while it is unclear when Wyoming will legalize cannabis, it is known that the state is exploring legal options with regard to legalization.

The reason for the state turning to its legal counterparts for information on cannabis legalization may be data that shows that the state’s residents are looking for more access to marijuana. Additionally, data from a study conducted in December 2020 by the University of Wyoming showed that 54% of the state’s residents supported the herb’s legalization and, in particular, adult-use marijuana.

The report claimed that a steady rise in support was observed from 2014 to 2018 and shows that the support in legalization grew from 37% in 2014 to 41% then 49% in 2016 and 2018, respectively.

Chief of police in Sheridan, Wyoming, Travis Koltiska, feels that trafficking marijuana across state lines will not be stopping any time soon. In fact, he notes, there may even be an increase, especially when the data above is taken into consideration.

Sheridan County Sheriff Allen Thompson added that bigger legal operations in the states that surround Wyoming have shown an increased availability in the amounts of cannabis that are distributed, adding that this will likely grow. He noted that residents of Wyoming did travel to other states to obtain marijuana, explaining that this number could grow in the future.

In addition to the data mentioned above, three out of every four people who live in the state believe that individuals caught in possession of marijuana shouldn’t serve jail time. This shows a general increase in acceptance of cannabis legalization, as this number was at 66% in 2014, before growing to 69% in 2018.

However, many are still concerned that looking at marijuana legalization as a way to grow government revenue is not the best idea and other factors should be taken into account. Thompson explains that, while government revenue might grow in the short term if cannabis is legalized, he is concerned about the costs that will be paid in the long term with regard to the state’s public health system, which is already short on money and personal health.

Thompson proposes that efforts to legalize cannabis in the state should instead focus on factual education about the advantages and disadvantages of using cannabis, backing the health systems and centering on personal freedoms.

Away from the cannabis legalization debate in Wyoming, a number of companies are hitting it big through products that don’t contain the psychoactive THC. For example, CannAssist International Corp. (OTCQB: CNSC) was so successful that it was among the first U.S.-based CBD companies to go public on a major exchange.

NOTE TO INVESTORS: The latest news and updates relating to CannAssist International Corp. (OTCQB: CNSC) are available in the company’s newsroom at https://cnw.fm/CNSC

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

CBDNewsBreaks – CannAssist International Corporation (CNSC) Engages InvestorBrandNetwork for Corporate Communications Expertise

CannAssist (OTCQB: CNSC), a biotechnological pharmaceutical and wellness company marketing the Xceptol consumer brand, today announced its selection of the corporate communications expertise of the InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities. CannAssist is the owner of Xceptor Labs, a research and development and raw material manufacturing outfit leveraging its proprietary CiBiDinol technology to create CBD products it believes have better absorption than currently marketed oil-based products. “The cannabidiol market has been on fire since the 2018 Farm Bill was signed into law. In 2018, the global CBD market was valued at $4.6 billion, and it’s forecast to reach $23.6 billion by 2025, according to Grand View Research. CannAssist is uniquely positioned to capitalize on this market growth,” said IBN’s Director of Client Solutions Chris Johnson. “Based on current revenue from raw material sales, retail sales and the Xceptol brand’s international distribution, CannAssist expects to reach first-year sales of $5 million. We’re excited to customize our comprehensive suite of corporate communications solutions for the company as it seeks to expand its product pipeline and achieve steady sales growth in the years ahead.”

To view the full press release, visit https://cnw.fm/5cTbh

About CannAssist International Corporation

CannAssist produces and sells its cannabidiol (“CBD”) product, “CiBiDinol,” which is formulated based on a proprietary process developed by its founder, Mark Palumbo. CBD is a non-psychoactive compound found in hemp. CannAssist’s initial research and development work, aimed at enhancing the bioavailability of desired molecular structures, resulted in the creation of a line of CBD products, most notably its CBD product, CiBiDinol. CiBiDinol will be available in a line of consumable and topical products that the company believes will make enhanced CBD products more available and accessible to consumers. For more information, visit the company’s website at www.CannAssistInternational.com.

NOTE TO INVESTORS: The latest news and updates relating to CNSC are available in the company’s newsroom at https://cnw.fm/CNSC

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.